Compare Gilead Sciences, Inc. (GILD) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SMX Security Matters plc — how do they compare? Gilead Sciences, Inc. trades at $133.08 (market cap $163.51B), while SMX Security Matters plc trades at $19.78 (market cap $19.00M). The key difference: Gilead Sciences, Inc. is far larger — about 8605.8× SMX Security Matters plc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while SMX Security Matters plc pays none. Which is the better fit depends on your goals.
| GILD | SMX | |
|---|---|---|
Market Cap | $163.51B | $19.00M |
Sector | Health | Technology |
52-Week High | $155.80 | $295.56K |
52-Week Low | $108.22 | $12.87 |
Enterprise Value | $178.05B | $15.98M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
SMX trades at $20.08, up 14.74% over 24 hours, following two reverse stock splits in May and June 2026. Technical indicators are neutral to bearish, with support at $15 and resistance at $16. The company is focusing on its Circularity-as-a-Service platform for plastics traceability, capitalizing on regulatory shifts favoring recycled materials. However, profitability remains a concern with negative ROE and ROA.
The outlook hinges on SMX's ability to monetize its technology amid growing demand for verified recycled plastics. Key risks include execution challenges and persistent unprofitability. Analyst sentiment is mixed, with the stock's recent surge needing fundamental support to sustain momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
